BioCentury | Dec 23, 2020
Deals

Insilico caps year of deals by opening its computational platforms to pharmas’ in-house teams

Coming off a string of deals to discover targets and compounds on its partners’ behalf, Insilico Medicine has launched versions of its platforms that pharmas can use themselves. This year, Insilico Medicine Inc. made its...
BioCentury | Sep 16, 2020
Product Development

Pace of Monjuvi’s growth may dictate how quickly MorphoSys can rebuild its pipeline

MorphoSys’ first marketed therapeutic, Monjuvi, has the makings of a blockbuster, but the company and partner Incyte will need to execute on the drug’s launch and planned label expansions to generate the...
BioCentury | Mar 21, 2019
Company News

Celgene looks to AI company Exscientia to speed up small molecule discovery

Two months after backing Exscientia in a series B round, Celgene signed a three-year deal with the AI company to discover small molecules for three of Celgene's oncology and autoimmunity programs. Exscientia Ltd. (Oxford, U.K.)...
BioCentury | Jan 11, 2019
Finance

Exscientia looks inward

After spending six years building its artificial intelligence drug discovery platform and working with pharma partners, Exscientia Ltd. aims to use the bulk of the $26 million raised in a series B round to build...
BioCentury | Dec 31, 2016
Finance

Versant’s capstone

...capstone on a five-year transformation from a traditional, diversified West Coast healthcare VC to an international therapeutics-focused...
BioCentury | Nov 4, 2013
Company News

Dimension Therapeutics, ReGenX deal

ReGenX granted newco Dimension an exclusive, worldwide license to NAV vector technology and rights to undisclosed, preclinical programs in rare disease indications. Dimension will develop adeno-associated viral (AAV) vector gene therapies for rare diseases, with...
BioCentury | Feb 27, 2012
Emerging Company Profile

Kymab: More mAb diversity

Kymab Ltd. is developing its Kymouse transgenic mouse platform to generate a greater repertoire of human mAbs than it says can be done with competing technologies. With the Wellcome Trust backing the newco, management plans...
BioCentury | May 31, 2010
Company News

QLT, Valocor deal

Newco Valocor acquired QLT91382 , QLT418 and QLT450 from QLT and received exclusive, worldwide rights to QLT's lemuteporfin. QLT discontinued development of lemuteporfin in 2008 after a Phase I/II trial showed the topical photosensitizer did not...
BioCentury | Aug 4, 2008
Clinical News

Lemuteporfin: Phase I/II halted

QLT said it plans to halt development of lemuteporfin to treat acne after an interim review of data from a Phase I/II trial showed the product did not meet an internal therapeutic threshold. In 2006,...
BioCentury | Dec 4, 2007
Top Story

MorphoSys signs transformational deal

MorphoSys (FSE:MOR) and Novartis (NVS; SWX:NOVN) signed an antibody deal that should fund the biotech's next stages of internal therapeutic development. The agreement, an expansion of a 2004 deal, will give MOR $600 million over...
Items per page:
1 - 10 of 29
BioCentury | Dec 23, 2020
Deals

Insilico caps year of deals by opening its computational platforms to pharmas’ in-house teams

Coming off a string of deals to discover targets and compounds on its partners’ behalf, Insilico Medicine has launched versions of its platforms that pharmas can use themselves. This year, Insilico Medicine Inc. made its...
BioCentury | Sep 16, 2020
Product Development

Pace of Monjuvi’s growth may dictate how quickly MorphoSys can rebuild its pipeline

MorphoSys’ first marketed therapeutic, Monjuvi, has the makings of a blockbuster, but the company and partner Incyte will need to execute on the drug’s launch and planned label expansions to generate the...
BioCentury | Mar 21, 2019
Company News

Celgene looks to AI company Exscientia to speed up small molecule discovery

Two months after backing Exscientia in a series B round, Celgene signed a three-year deal with the AI company to discover small molecules for three of Celgene's oncology and autoimmunity programs. Exscientia Ltd. (Oxford, U.K.)...
BioCentury | Jan 11, 2019
Finance

Exscientia looks inward

After spending six years building its artificial intelligence drug discovery platform and working with pharma partners, Exscientia Ltd. aims to use the bulk of the $26 million raised in a series B round to build...
BioCentury | Dec 31, 2016
Finance

Versant’s capstone

...capstone on a five-year transformation from a traditional, diversified West Coast healthcare VC to an international therapeutics-focused...
BioCentury | Nov 4, 2013
Company News

Dimension Therapeutics, ReGenX deal

ReGenX granted newco Dimension an exclusive, worldwide license to NAV vector technology and rights to undisclosed, preclinical programs in rare disease indications. Dimension will develop adeno-associated viral (AAV) vector gene therapies for rare diseases, with...
BioCentury | Feb 27, 2012
Emerging Company Profile

Kymab: More mAb diversity

Kymab Ltd. is developing its Kymouse transgenic mouse platform to generate a greater repertoire of human mAbs than it says can be done with competing technologies. With the Wellcome Trust backing the newco, management plans...
BioCentury | May 31, 2010
Company News

QLT, Valocor deal

Newco Valocor acquired QLT91382 , QLT418 and QLT450 from QLT and received exclusive, worldwide rights to QLT's lemuteporfin. QLT discontinued development of lemuteporfin in 2008 after a Phase I/II trial showed the topical photosensitizer did not...
BioCentury | Aug 4, 2008
Clinical News

Lemuteporfin: Phase I/II halted

QLT said it plans to halt development of lemuteporfin to treat acne after an interim review of data from a Phase I/II trial showed the product did not meet an internal therapeutic threshold. In 2006,...
BioCentury | Dec 4, 2007
Top Story

MorphoSys signs transformational deal

MorphoSys (FSE:MOR) and Novartis (NVS; SWX:NOVN) signed an antibody deal that should fund the biotech's next stages of internal therapeutic development. The agreement, an expansion of a 2004 deal, will give MOR $600 million over...
Items per page:
1 - 10 of 29